CY1108076T1 - POLYSAKHARS WITH ANTI-THROUGH ACTIVITY CONTAINING ATTENTION IN A CO-OPERATIVE BINDING WITH BIOTINE OR A PRODUCER OF BIOTINE - Google Patents

POLYSAKHARS WITH ANTI-THROUGH ACTIVITY CONTAINING ATTENTION IN A CO-OPERATIVE BINDING WITH BIOTINE OR A PRODUCER OF BIOTINE

Info

Publication number
CY1108076T1
CY1108076T1 CY20071101542T CY071101542T CY1108076T1 CY 1108076 T1 CY1108076 T1 CY 1108076T1 CY 20071101542 T CY20071101542 T CY 20071101542T CY 071101542 T CY071101542 T CY 071101542T CY 1108076 T1 CY1108076 T1 CY 1108076T1
Authority
CY
Cyprus
Prior art keywords
biotine
polysakhars
producer
activity containing
operative binding
Prior art date
Application number
CY20071101542T
Other languages
Greek (el)
Inventor
Philippe Duchaussoy
Jean-Marc Herbert
Maurice Petitou
Pierre Savi
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Publication of CY1108076T1 publication Critical patent/CY1108076T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Η παρούσα εφεύρεση αφορά σε νέους συνθετικούς πολυσακχαρίτες οι οποίοι σχηματίζουν τουλάχιστον έναν ομοιοπολικό δεσμό με τη βιοτίνη ή ένα παράγωγο της βιοτίνης καθώς και με μία μέθοδο η οποία χρησιμοποιεί την αβιδίνη ή τη στρεπταβιδίνη οι οποίες επιτρέπουν την εξουδετέρωση των πολυσακχαριτών αυτών.The present invention relates to novel synthetic polysaccharides which form at least one covalent bond to the biotin or a biotin derivative as well as to a method employing avidin or streptavidin which permit neutralization of these polysaccharides.

CY20071101542T 2000-09-22 2007-12-04 POLYSAKHARS WITH ANTI-THROUGH ACTIVITY CONTAINING ATTENTION IN A CO-OPERATIVE BINDING WITH BIOTINE OR A PRODUCER OF BIOTINE CY1108076T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0012094A FR2814463B1 (en) 2000-09-22 2000-09-22 NOVEL POLYSACCHARIDES WITH ANTITHROMBOTIC ACTIVITY COMPRISING AT LEAST ONE COVALENT BINDING WITH BIOTIN OR A BIOTINE DERIVATIVE
EP01972171A EP1322673B1 (en) 2000-09-22 2001-09-20 Polysaccharides with antithrombotic activity comprising at least a covalent bond with biotin or a biotin derivative

Publications (1)

Publication Number Publication Date
CY1108076T1 true CY1108076T1 (en) 2014-02-12

Family

ID=8854579

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071101542T CY1108076T1 (en) 2000-09-22 2007-12-04 POLYSAKHARS WITH ANTI-THROUGH ACTIVITY CONTAINING ATTENTION IN A CO-OPERATIVE BINDING WITH BIOTINE OR A PRODUCER OF BIOTINE

Country Status (40)

Country Link
US (3) US6844329B2 (en)
EP (1) EP1322673B1 (en)
JP (2) JP5016778B2 (en)
KR (2) KR100891388B1 (en)
CN (1) CN1235914C (en)
AR (1) AR030774A1 (en)
AT (1) ATE374215T1 (en)
AU (2) AU2001291960C1 (en)
BG (1) BG66191B1 (en)
BR (1) BR0114007A (en)
CA (1) CA2418815C (en)
CY (1) CY1108076T1 (en)
CZ (1) CZ300856B6 (en)
DE (1) DE60130669T2 (en)
DK (1) DK1322673T3 (en)
EA (1) EA005133B1 (en)
EC (1) ECSP034514A (en)
EE (1) EE05202B1 (en)
ES (1) ES2292625T3 (en)
FR (1) FR2814463B1 (en)
GE (1) GEP20053616B (en)
HK (1) HK1053316A1 (en)
HR (1) HRP20030219B1 (en)
HU (2) HU1400034D0 (en)
IL (2) IL154848A0 (en)
IS (1) IS2550B (en)
ME (2) ME00080B (en)
MX (1) MXPA03002483A (en)
NO (2) NO332905B1 (en)
NZ (1) NZ524472A (en)
PE (1) PE20020471A1 (en)
PL (1) PL206727B1 (en)
PT (1) PT1322673E (en)
RS (1) RS50730B (en)
SI (1) SI1322673T1 (en)
SK (2) SK287054B6 (en)
TW (1) TWI308153B (en)
UA (1) UA79736C2 (en)
WO (1) WO2002024754A1 (en)
ZA (1) ZA200301692B (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2814463B1 (en) * 2000-09-22 2002-11-15 Sanofi Synthelabo NOVEL POLYSACCHARIDES WITH ANTITHROMBOTIC ACTIVITY COMPRISING AT LEAST ONE COVALENT BINDING WITH BIOTIN OR A BIOTINE DERIVATIVE
FR2874924B1 (en) 2004-09-09 2006-12-01 Sanofi Aventis Sa BIOTINYLATED HEXADECASACCHARIDES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
TWI403334B (en) * 2004-12-23 2013-08-01 Merck Sharp & Dohme Antithrombotic dual inhibitors comprising a biotin residue
TWI376234B (en) * 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
KR20080055960A (en) * 2005-10-10 2008-06-19 엔.브이.오가논 Anticoagulant antithrombotic dual inhibitors comprising a biotin label
ES2362011T3 (en) * 2005-10-10 2011-06-27 N.V. Organon ANTICOAGULANT ANTICHROGULATING DUAL INHIBITORS THAT INCLUDE A BIOTINE BRAND.
CN1317035C (en) * 2005-10-24 2007-05-23 天津大学 Method for assembling multi-biological functional factor on micro-particle surface based on hydrazide group
EP1886696A1 (en) * 2006-08-03 2008-02-13 Endotis Pharma Conjugates of antithrombin binding oligosaccharide derivatives and therapeutic proteins
FR2912409B1 (en) * 2007-02-14 2012-08-24 Sanofi Aventis LOW MOLECULAR WEIGHT HEPARINS COMPRISING AT LEAST ONE BINDING WITH BIOTIN OR A BIOTIN DERIVATIVE OF THEIR PREPARATION METHOD, THEIR USE
EP2145624A1 (en) 2008-07-18 2010-01-20 Sanofi-Aventis Use of idrabiotaparinux for decreasing the incidence of bleedings during an antithrombotic treatment
TW201006479A (en) * 2008-07-18 2010-02-16 Sanofi Aventis Use of idrabiotaparinux for decreasing the incidence of bleedings during an antithrombotic treatment
EP2233143A1 (en) 2009-03-24 2010-09-29 Sanofi-Aventis Use of idrabiotaparinux for decreasing the incidence of bleedings during an antithrombotic treatment
FR2935386B1 (en) * 2008-08-26 2010-09-10 Sanofi Aventis NOVEL POLYSACCHARIDES WITH ANTITHROMBOTIC ACTIVITY COMPRISING A COVALENT LIAISON WITH AN AMINO CHAIN
EP2323605A4 (en) * 2008-09-10 2014-02-05 Syneron Medical Ltd Transdermal delivery of oligosaccharides
CA3014688A1 (en) 2008-12-19 2010-07-15 Supernus Pharmaceuticals, Inc. Use of molindone for the treatment of aggression, irritability, or impulsivity
FR2952935B1 (en) * 2009-11-20 2011-12-02 Sanofi Aventis PROCESS FOR THE PREPARATION OF SUCCINIMIDYL N-BIOTINYL-6-AMINOCAPROATE
CN102892411B (en) 2009-12-18 2015-01-21 恩多提斯药业公司 Pharmaceutical oral dosage form containing a synthetic oligosaccharide
CZ302510B6 (en) * 2010-03-29 2011-06-22 Univerzita Palackého v Olomouci Efficient method of biotinylation of compounds containing carboxyl group using solid phase synthesis for affinity chromatography needs
CZ302669B6 (en) * 2010-03-29 2011-08-24 Univerzita Palackého v Olomouci Efficient method of biotinylation of amino compounds using solid phase synthesis for affinity chromatography needs
WO2011123497A1 (en) 2010-03-31 2011-10-06 Supernus Pharmaceuticals Inc. Stabilized formulations of cns compounds
FR2964660B1 (en) * 2010-09-10 2012-09-28 Sanofi Aventis NOVEL BIOTINYL POLYSACCHARIDES WITH ANTITHROMBOTIC ACTIVITY AND IMPROVED METABOLIC STABILITY
EP2614089A1 (en) * 2010-09-10 2013-07-17 Sanofi-Aventis Biotinylated polysaccharides having an antithrombotic activity and improved metabolic stability
EP2484366A1 (en) 2011-02-07 2012-08-08 Sanofi Idrabiotaparinux for the treatment of pulmonary embolism and for the secondary prevention of venous thromboembolic events
WO2012172104A1 (en) 2011-06-17 2012-12-20 Endotis Pharma Synthetic pentasaccharides having short half-life and high activity
AU2013344920A1 (en) * 2012-11-13 2015-04-30 Supernus Pharmaceuticals, Inc. Method of treatment of aggression
WO2015195404A1 (en) 2014-06-20 2015-12-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for detection of an analyte by movement of tethered microparticles
WO2016205239A1 (en) 2015-06-15 2016-12-22 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Non-hormonal mammalian sperm decoy contraception based on the n-terminus of the zp2 protein
WO2018076025A1 (en) 2016-10-21 2018-04-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Molecular nanotags
CN108976318B (en) * 2017-06-01 2021-03-30 首都医科大学 Mono-6- (biotinimido) -6-deoxy-beta-cyclodextrin and preparation method and application thereof
WO2019133727A1 (en) 2017-12-29 2019-07-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Universal influenza virus probe set for enrichment of any influenza virus nucleic acid
CA3144968A1 (en) 2019-07-09 2021-01-14 Optimvia Llc Methods for synthesizing anticoagulant polysaccharides
CN114556685B (en) * 2019-10-17 2024-04-02 株式会社自动网络技术研究所 Wiring module
WO2022056078A1 (en) 2020-09-11 2022-03-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Rnase h-assisted detection assay for rna (radar)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3960884A (en) * 1974-04-24 1976-06-01 Sergei Ivanovich Zavyalov Method of preparing racemic biotin
AU563351C (en) * 1982-01-15 2003-06-19 Glaxo Group Limited Synthesis of oligosaccharides
IL102758A (en) * 1991-08-23 1997-03-18 Akzo Nv Glycosaminoglycanoid derivatives, their preparation and pharmaceutical compositions comprising them
WO2000002050A1 (en) * 1998-07-07 2000-01-13 Department Of Radiation Oncology, University Of Washington Trifunctional reagent for conjugation to a biomolecule
US20010023288A1 (en) * 1999-07-07 2001-09-20 Wilbur D. Scott Trifunctional reagent for conjugation to a biomolecule
FR2751334B1 (en) * 1996-07-19 1998-10-16 Sanofi Sa SYNTHETIC POLYSACCHARIDES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2773804B1 (en) * 1998-01-19 2000-02-18 Sanofi Sa SYNTHESIS POLYSACCHARIDES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
FR2773801B1 (en) * 1998-01-19 2000-05-12 Sanofi Sa NOVEL PENTASACCHARIDES, METHODS FOR THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
GB2335490B (en) * 1998-03-20 2003-05-14 Ortho Clinical Diagnostics An assay surface that permits an analyte releasiing step
US6492503B1 (en) 1998-07-31 2002-12-10 Seikagaku Corporation Glycosaminoglycan and drug compositions containing the same
FR2814463B1 (en) * 2000-09-22 2002-11-15 Sanofi Synthelabo NOVEL POLYSACCHARIDES WITH ANTITHROMBOTIC ACTIVITY COMPRISING AT LEAST ONE COVALENT BINDING WITH BIOTIN OR A BIOTINE DERIVATIVE

Also Published As

Publication number Publication date
EP1322673A1 (en) 2003-07-02
SK287054B6 (en) 2009-10-07
WO2002024754A1 (en) 2002-03-28
YU19703A (en) 2006-05-25
DK1322673T3 (en) 2008-01-14
KR100891388B1 (en) 2009-04-02
NO332905B1 (en) 2013-01-28
EP1322673B1 (en) 2007-09-26
KR20080049139A (en) 2008-06-03
PE20020471A1 (en) 2002-06-01
FR2814463A1 (en) 2002-03-29
US8318696B2 (en) 2012-11-27
JP5016778B2 (en) 2012-09-05
ES2292625T3 (en) 2008-03-16
AU2001291960C1 (en) 2009-10-08
CA2418815C (en) 2011-05-10
GEP20053616B (en) 2005-09-26
SK287218B6 (en) 2010-03-08
CN1235914C (en) 2006-01-11
CN1466594A (en) 2004-01-07
DE60130669T2 (en) 2008-07-17
EA200300237A1 (en) 2003-08-28
NO20110401L (en) 2003-05-22
ME00080B (en) 2010-10-10
IS6733A (en) 2003-02-28
MXPA03002483A (en) 2004-05-24
WO2002024754A8 (en) 2003-07-03
CZ300856B6 (en) 2009-08-26
FR2814463B1 (en) 2002-11-15
CZ2003814A3 (en) 2003-06-18
IS2550B (en) 2009-10-15
BG107650A (en) 2003-11-28
CA2418815A1 (en) 2002-03-28
PL206727B1 (en) 2010-09-30
US20040024197A1 (en) 2004-02-05
HK1053316A1 (en) 2003-10-17
AU9196001A (en) 2002-04-02
ECSP034514A (en) 2003-04-25
US20110144042A1 (en) 2011-06-16
AU2001291960B2 (en) 2007-03-01
PL363368A1 (en) 2004-11-15
HUP0303551A3 (en) 2004-03-29
US6844329B2 (en) 2005-01-18
EA005133B1 (en) 2004-12-30
BG66191B1 (en) 2011-12-30
MEP23608A (en) 2010-06-10
ATE374215T1 (en) 2007-10-15
US7943595B2 (en) 2011-05-17
HRP20030219A2 (en) 2003-06-30
DE60130669D1 (en) 2007-11-08
HRP20030219B1 (en) 2011-10-31
RS50730B (en) 2010-08-31
SK3562003A3 (en) 2003-11-04
TWI308153B (en) 2009-04-01
IL154848A (en) 2010-11-30
US20060160768A1 (en) 2006-07-20
IL154848A0 (en) 2003-10-31
BR0114007A (en) 2003-08-12
ZA200301692B (en) 2004-03-01
KR20030055269A (en) 2003-07-02
EE200300114A (en) 2005-02-15
JP2004509902A (en) 2004-04-02
HUP0303551A2 (en) 2004-03-01
PT1322673E (en) 2007-12-03
SI1322673T1 (en) 2008-02-29
AR030774A1 (en) 2003-09-03
NZ524472A (en) 2004-10-29
UA79736C2 (en) 2007-07-25
NO20031295D0 (en) 2003-03-20
NO20031295L (en) 2003-05-22
JP2012131809A (en) 2012-07-12
EE05202B1 (en) 2009-08-17
HU1400034D0 (en) 2004-03-01

Similar Documents

Publication Publication Date Title
CY1108076T1 (en) POLYSAKHARS WITH ANTI-THROUGH ACTIVITY CONTAINING ATTENTION IN A CO-OPERATIVE BINDING WITH BIOTINE OR A PRODUCER OF BIOTINE
CY1105295T1 (en) TREATMENT OF AUTOIMMUNE DISEASES WITH ANTAGONISTS THAT BIND TO B CELL SURFACE MARKERS
CY1107494T1 (en) SUBSTITUTED PYRIDYLMETHYLPEPAZINE AND PIPEPIDINE PRODUCERS, THEIR PREPARATION AND THEIR USE FOR CENTRAL NAVY DISEASES
TR199900781T2 (en) H�cre yap��ma inhibit�rleri
TR200102342T2 (en) Freeze-dried substance containing paramilon, its production and use.
DE69827370D1 (en) CLOTHING FOR SPORTSHOES
CY1107474T1 (en) USE 13C-NMR TO DETECT CONNECTION
IT8720641A0 (en) POLYOLEFINS. PIPERIDINE-TRIAZINE COMPOUNDS USABLE AS STABILIZERS
ATE316531T1 (en) CONDENSED DIHYDROCINOLINONE DERIVATIVES FOR INHIBITING MRP1
GR920100527A (en) New oligodeoxyribonucleotides having anti-ischemic activity and methods of preparation thereof.
IT8721320A0 (en) PIPERIDIN TRIAZINE COMPOUNDS USABLE AS STABILIZERS FOR SYNTHETIC POLYMERS.
ATE414795T1 (en) ANTIBODIES LIBRARIES
CY1105675T1 (en) PROTEIN ROSDENOUS ANGIOSTATIN
CY1110418T1 (en) Suspension of Interaction between Oxidated Proteins and CD36 - Their Mechanism of Action
NL185635C (en) METHOD FOR MANUFACTURING A SOUND BAR FOR PERCUSSION MUSIC INSTRUMENTS
DE29508596U1 (en) Lighting arrangement for a translucent motif or information carrier
DE50114321D1 (en) RECEPTOR OF EDB FIBRONECTINE DOMAIN (II)
AR019627A1 (en) COMBINATORY SYNTHESIS OF MULTIPLE LINK LIBRARIES
DE59813664D1 (en) PROCESS FOR SCREENING ANTIMYCOTIC ACTIVE SUBSTANCES
ES2189390T3 (en) FUNGICIDES
CY1110444T1 (en) METHODS FOR CONVERTING THE INTERFERENCE AND ITS PRODUCTS
IT8720750A0 (en) BICYCLIC PIPERIDINE COMPOUNDS USABLE AS STABILIZERS FOR SYNTHETIC POLYMERS.
TR199701527T1 (en) Process for the synthesis of benzo(b)thiophenes.
IT7830625V0 (en) BAMBOLOTTO WITH WHICH MUSICAL NOTES ARE OBTAINED, BY PRIZING IT.
CY1117515T1 (en) AN IMPROVED METHOD FOR COMPOSITION OF MOLECULAR MODELS